Equities research analysts at Oppenheimer Holdings Inc. assumed coverage on shares of Syros Pharmaceuticals Inc. (NASDAQ:SYRS) in a research note issued on Tuesday. The firm set an “outperform” rating on the stock.

Other equities analysts have also issued reports about the stock. Piper Jaffray Cos. set a $20.00 price objective on shares of Syros Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, November 14th. Zacks Investment Research upgraded shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, October 20th. HC Wainwright restated a “hold” rating and issued a $10.00 price objective on shares of Syros Pharmaceuticals in a research report on Friday, September 9th. Wedbush restated an “outperform” rating and issued a $18.00 price objective on shares of Syros Pharmaceuticals in a research report on Monday, November 14th. Finally, Cann initiated coverage on shares of Syros Pharmaceuticals in a research report on Monday. They issued an “outperform” rating and a $28.00 price objective for the company. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $19.60.

Analyst Recommendations for Syros Pharmaceuticals (NASDAQ:SYRS)

Syros Pharmaceuticals (NASDAQ:SYRS) traded up 5.33% during trading on Tuesday, reaching $14.04. 1,954 shares of the company’s stock traded hands. Syros Pharmaceuticals has a 12 month low of $8.16 and a 12 month high of $21.50. The firm has a 50 day moving average price of $13.48 and a 200-day moving average price of $13.08. The firm’s market cap is $328.26 million.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its quarterly earnings data on Monday, November 14th. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.54) by $0.11. On average, analysts forecast that Syros Pharmaceuticals will post ($4.03) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This story was first posted by Financial Market News and is owned by of Financial Market News. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The legal version of this story can be viewed at http://www.financial-market-news.com/syros-pharmaceuticals-inc-syrs-research-coverage-started-at-oppenheimer-holdings-inc/1208464/.

A number of large investors have recently made changes to their positions in the stock. California State Teachers Retirement System bought a new stake in shares of Syros Pharmaceuticals during the third quarter valued at about $137,000. Spark Investment Management LLC acquired a new stake in shares of Syros Pharmaceuticals during the third quarter worth $160,000. Hamilton Lane Advisors LLC acquired a new stake in shares of Syros Pharmaceuticals during the third quarter worth $193,000. Morgan Stanley acquired a new stake in shares of Syros Pharmaceuticals during the third quarter worth $469,000. Finally, AWM Investment Company Inc. acquired a new stake in shares of Syros Pharmaceuticals during the third quarter worth $660,000. Institutional investors and hedge funds own 54.56% of the company’s stock.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing treatments for cancer and immune-mediated diseases. The Company’s gene control platform focuses on identifying gene control targets linked to genomically defined patient populations, and drugging gene control targets.

5 Day Chart for NASDAQ:SYRS

Receive News & Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.